News
ALPMY
14.10
-1.26%
-0.18
Citi Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
TipRanks · 8h ago
Weekly Report: what happened at ALPMY last week (0112-0116)?
Weekly Report · 16h ago
Weekly Report: what happened at ALPMY last week (0105-0109)?
Weekly Report · 01/12 09:27
Weekly Report: what happened at ALPMY last week (1229-0102)?
Weekly Report · 01/05 09:26
Weekly Report: what happened at ALPMY last week (1222-1226)?
Weekly Report · 12/29/2025 09:25
Weekly Report: what happened at ALPMY last week (1215-1219)?
Weekly Report · 12/22/2025 09:25
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
NASDAQ · 12/18/2025 06:14
Merck's Keytruda-Padcev Combo Boosts Survival In Pivotal Bladder Cancer Trial
Benzinga · 12/17/2025 17:45
Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study
Dow Jones · 12/17/2025 12:38
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
Seeking Alpha · 12/17/2025 12:23
Why Is Monte Rosa Stock Trading Higher Today?
Benzinga · 12/16/2025 19:37
Weekly Report: what happened at ALPMY last week (1208-1212)?
Weekly Report · 12/15/2025 09:27
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
Seeking Alpha · 12/12/2025 15:38
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Seeking Alpha · 12/10/2025 15:26
Weekly Report: what happened at ALPMY last week (1201-1205)?
Weekly Report · 12/08/2025 09:27
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study
Seeking Alpha · 12/05/2025 21:48
Weekly Report: what happened at ALPMY last week (1124-1128)?
Weekly Report · 12/01/2025 09:25
EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer
NASDAQ · 12/01/2025 01:42
Weekly Report: what happened at ALPMY last week (1117-1121)?
Weekly Report · 11/24/2025 09:27
Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
NASDAQ · 11/22/2025 04:01
More
Webull provides a variety of real-time ALPMY stock news. You can receive the latest news about Astellas Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ALPMY
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.